Would you consider APBI in a patient who meets all criteria but has high-risk genomic testing and is not receiving chemotherapy?

I would proceed with APBI 30 in 5 as it has a boost dose built in to account for a high genomic score.

In general, the commercial genomic tests (i.e., Oncotype DX and MammaPrint) were designed and widely tested as predictors of distant metastatic recurrence and thus escalation of adjuvant systemic therapies; however, several studies have subsequently demonstrated them also as predictors of LRR, which...